Agile Therapeutics (NASDAQ:AGRX) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Agile Therapeutics (NASDAQ:AGRX) in a research note issued to investors on Friday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Agile Therapeutics Price Performance

Agile Therapeutics stock opened at $1.51 on Friday. Agile Therapeutics has a one year low of $0.20 and a one year high of $2.63. The business’s fifty day moving average is $1.48 and its 200 day moving average is $0.90. The stock has a market capitalization of $10.35 million, a PE ratio of -0.41 and a beta of 1.58.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Monday, August 12th. The specialty pharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter. The firm had revenue of $5.58 million for the quarter.

Institutional Trading of Agile Therapeutics

A hedge fund recently raised its stake in Agile Therapeutics stock. Armistice Capital LLC grew its holdings in Agile Therapeutics, Inc. (NASDAQ:AGRX) by 10.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 108,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 10,000 shares during the period. Armistice Capital LLC owned 3.65% of Agile Therapeutics worth $211,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.92% of the company’s stock.

About Agile Therapeutics

Agile Therapeutics, Inc, a women's healthcare company, engages in the research, development, and commercialization of prescription contraceptive products for women in the United States. It offers Twirla, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.